查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
酒糟市場—全球及區域分析：按藥物類別、給藥途徑、最終用戶機構和地區分類—分析與預測（2025-2035）
市場調查報告書
商品編碼
1856054

酒糟市場—全球及區域分析：按藥物類別、給藥途徑、最終用戶機構和地區分類—分析與預測（2025-2035）

Rosacea Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, End Users, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

全球酒糟市場分析與預測：2025-2035年

酒糟是一種慢性發炎性皮膚病，主要影響臉部，導致持續發紅、可見的血管和類似痤瘡的丘疹。

酒渣鼻最常出現在鼻子、臉頰、額頭和下巴，但也可能涉及頸部、胸部，偶爾也會牽扯到眼睛，這種情況稱為酒糟。症狀的嚴重程度各不相同，會隨時間波動，常常反覆發作和緩解。典型的徵兆包括潮紅、刺痛或灼熱感、粗糙或鱗屑狀斑塊、紅色或充滿膿液的丘疹以及毛細血管擴張（可見的血管）。在膚色較深的人群中，酒糟可能表現為褐色色素沉著或棕褐色丘疹，因此更難被發現。病情發展會導致皮膚增厚，尤其是在鼻子部位（酒渣鼻），以及眼部炎症，如果不及時治療，可能會發展為視力併發症。

全球酒糟市場成長主要受以下幾個關鍵因素驅動。其中一個關鍵促進因素是酒糟在成年人（尤其是30至60歲人群）中的盛行率不斷上升，這推動了已開發市場和新興市場對該疾病的認知度和診斷率的提高。另一個關鍵促進因素是新型療法（如米諾四環素環素Emlogi和羥甲唑啉Lofade）獲得監管部門核准，從而拓展了傳統抗生素以外的治療選擇。此外，遠距皮膚病學和網路藥局平台的快速普及使患者能夠遠端獲得及時的診斷和治療，提高了治療的可及性，尤其是在皮膚科基礎設施薄弱的地區。這些因素共同促進了治療的廣泛應用和市場的擴張。

全球酒糟市場面臨許多限制和挑戰，阻礙其發展。其中一個主要障礙是品牌藥物（如舒利達和歐瑞西亞）價格昂貴，限制了許多患者（尤其是用戶和無保險患者）的負擔能力和用藥途徑。此外，治療相關的副作用，如皮膚刺激、乾燥和灼熱感，常常導致患者依從性差，甚至中斷治療，從而降低整體療效。另一個關鍵挑戰是深色皮膚人群中酒糟的診斷不足，他們的症狀可能不會表現為典型的皮膚發紅，因此難以識別和治療。這些限制凸顯了開發更經濟實惠、耐受性更好、更全面的治療和診斷方法的必要性。

由於創新產品開發、策略聯盟以及對精準皮膚病學的日益重視，全球酒糟市場的競爭格局正在迅速演變。包括高德美（Galderma SA）、艾伯維（AbbVie Inc.）、博士倫（Bausch Health）、Journey Medical Corporation 和 Sol-Gel Technologies 在內的主要公司正積極投資於研究和臨床試驗，以開發針對不同亞型酒糟的先進治療方法。這些努力包括推出非抗生素療法、緩釋性口服製劑以及耐受性較佳的外用製劑，以達到長期症狀控制。各公司也透過數位健康夥伴關係、支持遠距皮膚病學平台以及透過網路藥局網路擴大產品覆蓋範圍來拓展市場。同時，各公司緊跟新興趨勢，研發對微生物友善、潔淨標示且對敏感肌膚友善的產品，以滿足消費者對永續和個人化護膚的偏好。這種以創新主導、以患者為中心的策略正在塑造一個以療效、安全性、可及性和長期疾病管理為核心的動態酒糟市場格局。

在全球酒糟市場蓬勃發展的背景下，多個新興機會正推動著市場顯著成長。包括JAK抑制劑和TRPV1抑制劑在內的標靶治療，在治療中重度酒糟方面，相較於傳統治療方法，具有更高的精確度和更少的副作用。此外，亞太和拉丁美洲等新興市場的擴張，得益於可支配收入的成長、消費者健康意識的提高以及遠距遠端醫療和數位化皮膚科服務的快速普及，也為市場成長開闢了新的途徑。同時，隨著消費者對環保、無微塑膠和親膚護膚產品的需求日益成長，市場正朝著永續和潔淨標示配方發展。這些趨勢為配方科學的創新打開了大門，提升了品牌在日益成長的健康意識和健康理念主導的市場中的競爭力。

市場區隔

細分 1：依藥物類別

  • α腎上腺素促效劑
  • 抗生素（四環黴素、大環內酯類）
  • 壬二酸及其衍生物
  • 伊維菌素
  • 過氧化苯甲醯及其他

細分 2：依給藥途徑

  • 局部的
  • 口服
  • 其他（注射、器械輔助）

細分3：依最終用戶設施分類

  • 醫院
  • 皮膚科診所
  • 居家醫療

細分 4：按地區

  • 北美洲
  • 歐洲
  • 亞太地區

全球酒糟市場正經歷著幾個顯著的趨勢，這些趨勢正在重塑治療和護理模式。其中一個關鍵趨勢是轉向非抗生素和對微生物友善的療法，這主要是由於人們日益關注抗生素抗藥性和長期皮膚健康問題。此外，人工智慧 (AI) 和遠距皮膚病學的融合正在提升早期診斷、治療可近性和個人化護理水平，尤其是在醫療資源匱乏的地區。另一個新興趨勢是個人化護膚和皮膚美容解決方案的興起。消費者正在尋求溫和、多功能的產品，這些產品不僅能夠緩解症狀，還能維護皮膚屏障健康。

市場的一個關鍵趨勢是轉向非抗生素和對微生物友好的療法，這主要受人們對抗生素抗藥性和長期皮膚健康的日益關注所驅動。皮膚微生物組調節劑的研發已成為一項關鍵創新，旨在透過恢復皮膚的自然平衡和減少炎症，提供有針對性且有效的症狀管理。此外，人工智慧 (AI) 和遠距皮膚病學的結合正在提升早期診斷、治療可近性和個人化護理水平，尤其是在服務不足的地區。另一個新興趨勢是個人化護膚和皮膚美容解決方案的興起。消費者正在尋求溫和、多功能的產品，這些產品不僅能夠緩解症狀，還能維護皮膚屏障健康。對純素化妝品和個人護理成分日益成長的需求反映了精準皮膚病學、數位健康融合和永續產品創新等更廣泛的趨勢，並進一步影響產品配方。

目錄

執行摘要

第1章 全球酒糟市場：產業分析

  • 市場概覽與生態系統
  • 價值鏈分析
  • 主要市場趨勢
  • 監管狀態
  • 市場動態
    • 概述
    • 市場促進因素
    • 市場限制
    • 市場機遇

2. 全球酒糟市場（按藥物類別分類），價值，2023-2035年

  • α-腎上腺素促效劑
  • 抗生素（四環黴素、大環內酯類）
  • 壬二酸及其衍生物
  • 伊維菌素
  • 過氧化苯甲醯醯等

3. 全球酒糟市場（依給藥途徑分類），價值，2023-2035年

  • 局部的
  • 口服
  • 其他（注射、設備支援）

第4章 全球酒糟市場（按終端用戶設施分類），價值，2023-2035年

  • 醫院
  • 皮膚科診所
  • 居家醫療

第5章：全球酒糟市場（按地區分類），價值，2023-2035年

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

6. 全球酒糟市場競爭格局及公司概況

  • 競爭格局
  • 公司簡介
    • Galderma SA
    • Bausch Health Companies Inc.
    • AbbVie Inc.
    • Leo Pharma A/S
    • Journey Medical Corporation
    • Sol-Gel Technologies Ltd.
    • Novan, Inc.
    • Almirall SA
    • Pfizer Inc
    • Johnson & Johnson (Janssen)
    • 其他

第7章調查方法

Product Code: BHL3352SA

Global Rosacea Market, Analysis and Forecast: 2025-2035

Rosacea is a chronic inflammatory skin condition that primarily affects the face, leading to persistent redness, visible blood vessels, and acne-like bumps. While it most commonly appears on the nose, cheeks, forehead, and chin, it can also extend to the neck, chest, and in some cases, the eyes a form known as ocular rosacea. Symptoms vary in severity and may fluctuate over time, often alternating between flare-ups and remission. The hallmark signs include facial flushing, tingling or burning sensations, rough or scaly patches, red or pus-filled bumps, and telangiectasia (visible blood vessels). In individuals with darker skin tones, rosacea may present as brown discoloration or yellow-brown bumps, making it more difficult to detect. Advanced cases may lead to thickened skin, especially on the nose (rhinophyma), and eye irritation, which can progress to vision complications if left untreated.

The growth of the global rosacea market is primarily driven by several key factors. A major driver is the rising prevalence of rosacea among adults, particularly those aged 30 to 60, coupled with increasing awareness and diagnosis rates across both developed and emerging markets. Another important driver is the regulatory approval of novel therapies, such as Emrosi (minocycline ER) and Rhofade (oxymetazoline), which are expanding treatment options beyond traditional antibiotics. Additionally, the rapid adoption of teledermatology and e-pharmacy platforms is improving access to care, enabling patients to receive timely diagnosis and treatment remotely-especially in regions with limited dermatology infrastructure. These factors collectively contribute to greater treatment uptake and market

The global rosacea market faces several restraints and challenges that can hinder its growth. One significant barrier is the high cost of branded medications, such as Soolantra and Oracea, which limits affordability and access for many patients, particularly in low-income or uninsured populations. Additionally, treatment-related side effects, including skin irritation, dryness, and burning sensations, often lead to poor adherence and discontinuation, reducing overall treatment effectiveness. Another critical challenge is the underdiagnosis of rosacea in individuals with darker skin tones, where symptoms may not present as classic redness, making the condition harder to recognize and treat. These limitations highlight the need for more affordable, well-tolerated, and inclusive treatment and diagnostic approaches.

The competitive landscape of the global rosacea market is evolving rapidly, driven by innovative product development, strategic collaborations, and a growing focus on precision dermatology. Key players such as Galderma S.A., AbbVie Inc., Bausch Health, Journey Medical Corporation, and Sol-Gel Technologies are actively investing in research and clinical trials to develop advanced therapies targeting various subtypes of rosacea. These efforts include the introduction of non-antibiotic treatments, extended-release oral formulations, and topical agents with improved tolerability for long-term symptom control. Companies are also enhancing their presence through digital health partnerships, supporting teledermatology platforms and expanding access via e-pharmacy networks. In parallel, firms are aligning with emerging trends by formulating microbiome-friendly, clean-label, and sensitive skin-compatible products that appeal to consumer preferences for sustainable and personalized skincare. This innovation-driven and patient-centric approach is shaping a dynamic rosacea market landscape centered on efficacy, safety, accessibility, and long-term disease management.

The global rosacea market is poised for significant growth, fueled by several emerging opportunities. A key area of advancement lies in targeted therapies, including JAK and TRPV1 inhibitors, which offer the potential to treat moderate to severe forms of rosacea with enhanced precision and reduced side effects compared to traditional treatments. Additionally, expansion in emerging markets such as Asia-Pacific and Latin America is creating new avenues for growth, driven by rising disposable incomes, increasing awareness, and the rapid adoption of telehealth and digital dermatology services. Furthermore, the market is witnessing a shift toward sustainable and clean-label formulations, as consumers increasingly seek eco-friendly, microplastic-free, and gentle skincare solutions. These trends are opening the door for innovation in formulation science and offering brands a competitive edge in an increasingly conscious and wellness-driven marketplace.

Market Segmentation:

Segmentation 1: by Drug Class

  • Alpha-adrenergic Agonists
  • Antibiotics (Tetracyclines, Macrolides)
  • Azelaic Acid & Derivatives
  • Ivermectin
  • Benzoyl Peroxide & Others

Segmentation 2: by Route of Administration

  • Topical
  • Oral
  • Others (Injectables, Device-assisted)

Segmentation 3: by End Users Facility

  • Hospitals
  • Dermatology Clinics
  • Home-care Settings

Segmentation 4: by Region

  • North America
  • Europe
  • Asia-Pacific

The global rosacea market is witnessing several notable trends that are reshaping its treatment and care landscape. One key trend is the shift toward non-antibiotic and microbiome-friendly therapies, driven by growing concerns over antibiotic resistance and long-term skin health. Additionally, the integration of artificial intelligence (AI) and teledermatology is enhancing early diagnosis, treatment access, and personalized care, particularly in underserved regions. Another emerging trend is the rise of personalized skincare and dermo-cosmetic solutions, as consumers seek gentle, multifunctional products that not only manage symptoms but also support skin barrier health.

One key trend in the market is the shift toward non-antibiotic and microbiome-friendly therapies, driven by growing concerns over antibiotic resistance and long-term skin health. The development of skin microbiome modulators is emerging as a significant innovation, aimed at restoring the natural balance of skin flora and reducing inflammation, thereby offering targeted and effective symptom management. Additionally, the integration of artificial intelligence (AI) and teledermatology is enhancing early diagnosis, treatment access, and personalized care, particularly in underserved regions. Another emerging trend is the rise of personalized skincare and dermo-cosmetic solutions, as consumers seek gentle, multifunctional products that not only manage symptoms but also support skin barrier health. The growing demand for vegan cosmetics and personal care ingredients further influences product formulation, reflecting a broader move toward precision dermatology, digital health integration, and sustainable product innovation.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Rosacea Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Value chain Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Market Dynamics
    • 1.5.1 Overview
    • 1.5.2 Market Drivers
    • 1.5.3 Market Restraints
    • 1.5.4 Market Opportunities

2. Global Rosacea Market (by Drug Class), Value ($million), 2023-2035

  • 2.1 Alpha-adrenergic Agonists
  • 2.2 Antibiotics (Tetracyclines, Macrolides)
  • 2.3 Azelaic Acid & Derivatives
  • 2.4 Ivermectin
  • 2.5 Benzoyl Peroxide & Others

3. Global Rosacea Market (by Route of Administration), Value ($million), 2023-2035

  • 3.1 Topical
  • 3.2 Oral
  • 3.3 Others (Injectables, Device-assisted)

4. Global Rosacea Market (by End-user Facility), Value ($million), 2023-2035

  • 4.1 Hospitals
  • 4.2 Dermatology Clinics
  • 4.3 Home-care Settings

5. Global Rosacea Market (by Region), Value ($Million), 2023-2035

  • 5.1 North America
    • 5.1.1 Market Dynamics
    • 5.1.2 Market Sizing and Forecast
    • 5.1.3 North America Rosacea Market, by Country ($Million), 2023-2035
      • 5.1.3.1 U.S.
      • 5.1.3.2 Canada
  • 5.2 Europe
    • 5.2.1 Market Dynamics
    • 5.2.2 Market Sizing and Forecast
    • 5.2.3 Europe Rosacea Market, by Country ($Million), 2023-2035
      • 5.2.3.1 U.K.
      • 5.2.3.2 France
      • 5.2.3.3 Germany
      • 5.2.3.4 Rest-of-Europe
  • 5.3 Asia-Pacific
    • 5.3.1 Market Dynamics
    • 5.3.2 Market Sizing and Forecast
    • 5.3.3 Asia-Pacific Rosacea Market, by Country ($Million), 2023-2035
      • 5.3.3.1 Japan
      • 5.3.3.2 China
      • 5.3.3.3 India
      • 5.3.3.4 Rest-of-Asia-Pacific
  • 5.4 Rest-of-the-World
    • 5.4.1 Market Dynamics
    • 5.4.2 Market Sizing and Forecast

6. Global Rosacea Market Competitive Landscape and Company Profiles

  • 6.1 Competitive Landscape
    • 6.1.1 Mergers and Acquisitions
    • 6.1.2 Partnership, Alliances and Business Expansion
    • 6.1.3 New Offerings
    • 6.1.4 Regulatory Activities
    • 6.1.5 Funding Activities
  • 6.2 Company Profiles
    • 6.2.1 Galderma S.A.
      • 6.2.1.1 Overview
      • 6.2.1.2 Top Products / Product Portfolio
      • 6.2.1.3 Top Competitors
      • 6.2.1.4 Target Customers/End-Users
      • 6.2.1.5 Key Personnel
      • 6.2.1.6 Analyst View
    • 6.2.2 Bausch Health Companies Inc.
      • 6.2.2.1 Overview
      • 6.2.2.2 Top Products / Product Portfolio
      • 6.2.2.3 Top Competitors
      • 6.2.2.4 Target Customers/End-Users
      • 6.2.2.5 Key Personnel
      • 6.2.2.6 Analyst View
    • 6.2.3 AbbVie Inc.
      • 6.2.3.1 Overview
      • 6.2.3.2 Top Products / Product Portfolio
      • 6.2.3.3 Top Competitors
      • 6.2.3.4 Target Customers/End-Users
      • 6.2.3.5 Key Personnel
      • 6.2.3.6 Analyst View
    • 6.2.4 Leo Pharma A/S
      • 6.2.4.1 Overview
      • 6.2.4.2 Top Products / Product Portfolio
      • 6.2.4.3 Top Competitors
      • 6.2.4.4 Target Customers/End-Users
      • 6.2.4.5 Key Personnel
      • 6.2.4.6 Analyst View
    • 6.2.5 Journey Medical Corporation
      • 6.2.5.1 Overview
      • 6.2.5.2 Top Products / Product Portfolio
      • 6.2.5.3 Top Competitors
      • 6.2.5.4 Target Customers/End-Users
      • 6.2.5.5 Key Personnel
      • 6.2.5.6 Analyst View
    • 6.2.6 Sol-Gel Technologies Ltd.
      • 6.2.6.1 Overview
      • 6.2.6.2 Top Products / Product Portfolio
      • 6.2.6.3 Top Competitors
      • 6.2.6.4 Target Customers/End-Users
      • 6.2.6.5 Key Personnel
      • 6.2.6.6 Analyst View
    • 6.2.7 Novan, Inc.
      • 6.2.7.1 Overview
      • 6.2.7.2 Top Products / Product Portfolio
      • 6.2.7.3 Top Competitors
      • 6.2.7.4 Target Customers/End-Users
      • 6.2.7.5 Key Personnel
      • 6.2.7.6 Analyst View
    • 6.2.8 Almirall S.A.
      • 6.2.8.1 Overview
      • 6.2.8.2 Top Products / Product Portfolio
      • 6.2.8.3 Top Competitors
      • 6.2.8.4 Target Customers/End-Users
      • 6.2.8.5 Key Personnel
      • 6.2.8.6 Analyst View
    • 6.2.9 Pfizer Inc
      • 6.2.9.1 Overview
      • 6.2.9.2 Top Products / Product Portfolio
      • 6.2.9.3 Top Competitors
      • 6.2.9.4 Target Customers/End-Users
      • 6.2.9.5 Key Personnel
      • 6.2.9.6 Analyst View
    • 6.2.10 Johnson & Johnson (Janssen)
      • 6.2.10.1 Overview
      • 6.2.10.2 Top Products / Product Portfolio
      • 6.2.10.3 Top Competitors
      • 6.2.10.4 Target Customers/End-Users
      • 6.2.10.5 Key Personnel
      • 6.2.10.6 Analyst View
    • 6.2.11 Others

7. Research Methodology

List of Figures

  • Figure: Rosacea Market (by Scenario), $Million, 2024, 2028, and 2035
  • Figure: Global Rosacea Market, 2024 and 2035
  • Figure: Global Rosacea Market Key Trends, Impact Analysis, 2023-2035
  • Figure: North America Rosacea Market, $Million, 2023-2035
  • Figure: Europe Rosacea Market, $Million, 2023-2035
  • Figure: Asia-Pacific Rosacea Market, $Million, 2023-2035
  • Figure: Rest of the World Rosacea Market, $Million, 2023-2035

List of Tables

  • Table: Market Snapshot
  • Table: Global Rosacea Market (by Drug Class), $Million, 2023-2035
  • Table: Global Rosacea Market (by Route of Administration), $Million, 2023-2035
  • Table: Global Rosacea Market (by End users), $Million, 2023-2035
  • Table: Global Rosacea Market (by Region), $Million, 2023-2035